Morgan Stanley Allogene Therapeutics, Inc. Transaction History

Morgan Stanley

$1.39 Trillion
Q4 2024

A detailed history of Morgan Stanley transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 998,596 shares of ALLO stock, worth $1.62 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

998,596

Previous 1,721,530 41.99%

Holding current value

$1.62 Million

Previous $4.82 Million 55.87%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$1.84 - $3.22 $1.33 Million - $2.33 Million	-722,934 Reduced 41.99%	998,596 $2.13 Million
Q3 2024 Nov 14, 2024	SELL	$2.08 - $3.5 $905,698 - $1.52 Million	-435,432 Reduced 20.19%	1,721,530 $4.82 Million
Q2 2024 Oct 17, 2024	SELL	$2.23 - $4.38 $167,254 - $328,508	-75,002 Reduced 3.36%	2,156,962 $5.03 Million
Q2 2024 Aug 14, 2024	SELL	$2.23 - $4.38 $167,254 - $328,508	-75,002 Reduced 3.36%	2,156,962 $5.03 Million
Q1 2024 Oct 17, 2024	BUY	$2.92 - $5.63 $219,005 - $422,261	75,002 Added 3.48%	2,231,964 $9.98 Million
Q1 2024 Aug 16, 2024	BUY	$2.92 - $5.63 $1.65 Million - $3.18 Million	564,138 Added 33.82%	2,231,964 $9.98 Million
Q1 2024 May 15, 2024	BUY	$2.92 - $5.63 $1.65 Million - $3.18 Million	564,138 Added 33.82%	2,231,964 $9.98 Million
Q4 2023 Aug 16, 2024	SELL	$2.28 - $3.5 $1.12 Million - $1.71 Million	-489,136 Reduced 22.68%	1,667,826 $5.35 Million
Q4 2023 Feb 13, 2024	BUY	$2.28 - $3.5 $652,326 - $1 Million	286,108 Added 20.71%	1,667,826 $5.35 Million
Q3 2023 Nov 15, 2023	BUY	$3.17 - $5.96 $159,390 - $299,674	50,281 Added 3.78%	1,381,718 $4.38 Million
Q2 2023 Aug 14, 2023	BUY	$4.53 - $6.74 $1.59 Million - $2.36 Million	349,962 Added 35.66%	1,331,437 $6.62 Million
Q1 2023 May 15, 2023	BUY	$4.92 - $8.21 $644,500 - $1.08 Million	130,996 Added 15.4%	981,475 $4.85 Million
Q4 2022 Feb 14, 2023	BUY	$5.62 - $11.11 $1.32 Million - $2.6 Million	234,460 Added 38.06%	850,479 $5.35 Million
Q3 2022 Nov 14, 2022	SELL	$10.32 - $17.28 $5.38 Million - $9.01 Million	-521,246 Reduced 45.83%	616,019 $6.65 Million
Q2 2022 Oct 27, 2022	SELL	$6.78 - $12.28 $3.74 Million - $6.77 Million	-551,176 Reduced 32.64%	1,137,265 $13 Million
Q2 2022 Aug 15, 2022	SELL	$6.78 - $12.28 $3.74 Million - $6.77 Million	-551,176 Reduced 32.64%	1,137,265 $13 Million
Q1 2022 Oct 27, 2022	BUY	$7.65 - $15.29 $4.22 Million - $8.43 Million	551,176 Added 48.47%	1,688,441 $15.4 Million
Q1 2022 May 13, 2022	BUY	$7.65 - $15.29 $3.23 Million - $6.46 Million	422,386 Added 33.36%	1,688,441 $15.4 Million
Q4 2021 Feb 14, 2022	BUY	$13.13 - $24.52 $2.67 Million - $4.98 Million	203,029 Added 19.1%	1,266,055 $18.9 Million
Q3 2021 Nov 15, 2021	BUY	$21.01 - $27.64 $22.3 Million - $29.4 Million	1,063,026 New	1,063,026 $27.3 Million

Others Institutions Holding ALLO

# of Institutions

177

Shares Held

139M

Call Options Held

75.8K

Put Options Held

52.8K

View Full List

About Allogene Therapeutics, Inc.

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $233M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

More about ALLO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account